Drug Interactions between Caltrate and interferon alfa-2b / ribavirin
This report displays the potential drug interactions for the following 2 drugs:
- Caltrate (calcium carbonate)
- interferon alfa-2b/ribavirin
Interactions between your drugs
No interactions were found between Caltrate and interferon alfa-2b / ribavirin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Caltrate
A total of 222 drugs are known to interact with Caltrate.
- Caltrate is in the following drug classes: antacids, minerals and electrolytes.
- Caltrate is used to treat the following conditions:
interferon alfa-2b / ribavirin
A total of 242 drugs are known to interact with interferon alfa-2b / ribavirin.
- Interferon alfa-2b / ribavirin is in the drug class antiviral combinations.
- Interferon alfa-2b / ribavirin is used to treat the following conditions:
Drug and food interactions
ribavirin food
Applies to: interferon alfa-2b / ribavirin
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.
MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.
References
- (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
- (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation
calcium carbonate food
Applies to: Caltrate (calcium carbonate)
ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
- Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.